Research progress in immune checkpoint inhibitors in the treatment of oncogenedriven advanced nonsmall cell lung cancer.
10.11817/j.issn.1672-7347.2020.190054
- Author:
Yuxin LI
1
;
Lemeng ZHANG
2
;
Jianhua CHEN
3
Author Information
1. First Department of Thoracic Medicine, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China. 56304724@qq.com.
2. First Department of Thoracic Medicine, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
3. First Department of Thoracic Medicine, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China. cjh_1000@163.com.
- Publication Type:Journal Article
- Keywords:
B-Raf proto-oncogene, serine/threonine kinase;
V-Ki-Ras2 Kirsten rat sarcoma viral oncogene homolog;
anaplastic lymphoma kinase;
driver genes;
epidermal growth factor receptor;
immune checkpoint inhibitors;
non-small cell lung cancer;
programmed cell death-ligand 1
- MeSH:
B7-H1 Antigen;
genetics;
Biomarkers, Tumor;
Carcinoma, Non-Small-Cell Lung;
drug therapy;
Humans;
Immunotherapy;
Lung Neoplasms;
drug therapy
- From:
Journal of Central South University(Medical Sciences)
2020;45(4):418-425
- CountryChina
- Language:English
-
Abstract:
The clinical application of immune checkpoint inhibitors (ICIs) lead to dramatic changes in the treatment strategy for patients with advanced non-small cell lung cancer (NSCLC), but the efficacy of ICIs in oncogene-driven NSCLC is controversial. Existing research shows that the efficacy of ICIs may be related to different types of driver genes, programmed cell death-ligand 1 (PD-L1) level, and tumor mutational burden (TMB). It may involved in other factors, such as clinical characteristics, and immune cell density. ICIs monotherapy or combination therapy may play a role in a subset of oncogene-driven NSCLC patients, but further studies are needed to select these patients, which may be an important direction for the future development of advanced NSCLC.
